Fermenta Biotech Ltd. (FERMENTA) — Tipsheet

Fermenta wins FSSAI nod for plant-based Vitamin D3

Tipsheet Editorial — Fri, 03 Jul 2026 19:17:51 GMT

VITADEE Green gets regulatory clearance, opening India's vegetarian supplement market for a micro-cap with trailing revenue decline.

What’s new

FSSAI approved Fermenta's plant-sourced Vitamin D3, VITADEE Green.
Product is developed and manufactured in India; commercial launch planned in FY27.
Approval adds to existing D3 portfolio and targets clean-label demand.

Why it matters

A micro-cap with trailing revenue down 13% just unlocked a new growth lane. Plant-based D3 is a fast-growing niche, but the financial impact is unquantified. The approval itself is the milestone, not the revenue it will generate.

What we’re watching

Speed and scale of the VITADEE Green commercial rollout.
Any revenue mention in FY27 quarterly results.
Competitor moves in the plant-based D3 space.

The full read

Fermenta Biotech has secured FSSAI approval for VITADEE Green, a plant-sourced Vitamin D3 developed and manufactured in India. For a micro-cap with a market cap of ₹1,072 crore and trailing revenue down 13%, regulatory clearances for differentiated products are rare. This one resolves regulatory uncertainty and enables commercial launch this fiscal year, tapping into the vegetarian supplement market. No financial estimates are attached. The move strengthens Fermenta's existing Vitamin D3 portfolio and aligns with clean-label trends. Now the test is execution.

Primary source: BSE · NSE

Fermenta's underlying business grew 26% even as PAT fell 8% on a high base

Tipsheet Editorial — Tue, 26 May 2026 16:50:58 GMT

Stripping out a prior-year real estate gain, Fermenta's operational revenue rose 26% and EBITDA jumped 44%. The headline PAT decline is an artefact of that one-off.

What’s new

FY26 PAT fell 8% to ₹70.3 cr, but that's due to a high base from a one-off real estate value unlock last year.
Underlying operational business revenue grew 26% and EBITDA grew 44% YoY.
Fermenta is advancing a vitamin D3 patent, EDQM certification, and GLAN approval, with commercial launches planned for FY27.

Why it matters

The headline numbers are misleading. The 8% PAT drop masks a strong operational year where the core business grew at a much faster clip than the topline suggests. The gap between operational growth (26% revenue, 44% EBITDA) and the reported figures (14% revenue, -8% PAT) tells the story of a business moving one way and a paper gain moving the other.

What we’re watching

FY27 commercial launches from the vitamin D3 patent, EDQM, and GLAN approvals.
Sustainability of the 44% operational EBITDA growth rate.
Whether the real estate asset base generates any further one-offs.

The full read

Fermenta Biotech's FY26 results require a second look. Headline PAT fell 8% to ₹70.3 crore, but that number is anchored to a prior-year profit boosted by a real estate value unlock. Strip that out, and the core business had a strong year: operational revenue climbed 26% and operational EBITDA surged 44%. The reported topline grew a more modest 14% to ₹547.8 crore, while consolidated EBITDA was essentially flat at ₹122.2 crore. The filing also points to product pipeline milestones, including a vitamin D3 patent, EDQM certification, and a GLAN approval, with commercial launches planned for the next fiscal year. The gap between the headline numbers and the operational reality is wide. Investors focused on the core business have a better story than the top-line suggests.

Primary source: BSE · NSE

Fermenta Biotech eyes NSE listing and a dilutive subsidiary deal

Tipsheet Editorial — Tue, 26 May 2026 16:38:13 GMT

The board approved an NSE direct-listing application and an in-principle private placement in a wholly-owned subsidiary that could dilute ownership.

What’s new

Board approved application for direct listing on the NSE after recent admission to the permitted category.
Granted 3,95,400 stock options at ₹83.67 per share.
Gave in-principle approval for a private placement in a wholly-owned subsidiary.

Why it matters

The NSE listing could improve liquidity for a stock not currently traded on the main exchange. The bigger strategic signal is the subsidiary private placement, which could dilute Fermenta's ownership in a unit it wholly owns today. Without terms or size, it is a statement of intent, not a deal.

What we’re watching

Details on the subsidiary private placement amount, valuation, and buyer.
Timeline for NSE listing and commencement of trading.
Whether the permitted category trading itself gains volume before the direct listing.

The full read

Fermenta Biotech's board approved an application for direct listing on the NSE, following its recent admission to the permitted category. The move could broaden the stock's investor base. It is still an early-stage application with no trading date. Separately, the board granted 3,95,400 stock options at ₹83.67 and reappointed a non-executive director. The more significant signal is the in-principle approval for a private placement in a wholly-owned subsidiary. If completed, that deal would dilute Fermenta's ownership in a unit it fully controls today. The filing provides no terms, size, or counterparty. Taken together, these are procedural steps: one to improve liquidity, one to compensate staff, and one that opens a door to potential structural change.

Primary source: BSE · NSE

Fermenta's profit falls 5% despite revenue growth, cushioned by a one-off

Tipsheet Editorial — Tue, 26 May 2026 14:32:06 GMT

Full-year net profit slipped to ₹64.28 crore as a ₹9.07 crore provision reversal masked tighter operational margins.

What’s new

FY26 standalone net profit fell 5% to ₹64.28 crore; revenue grew 4.6%.
A ₹9.07 crore provision reversal was an exceptional gain in the year.
The board recommended a final dividend of ₹3.75 per share.

Why it matters

The profit decline on revenue growth points to margin erosion. The one-off provision reversal makes the result look healthier than the core business performed.

What we’re watching

Q1 FY27 results for signs of margin recovery.
Management's explanation for the cost pressures that outpaced revenue growth.
Whether the dividend payout is maintained at this level.

The full read

Fermenta Biotech grew revenue 4.6% in FY26 but saw net profit slip 5% to ₹64.28 crore from ₹67.62 crore. A ₹9.07 crore provision reversal flattered the bottom line. Strip that out and the operational story is weaker than the headline. The auditors signed off clean, and the board proposed a ₹3.75 per share dividend. For a company posting top-line growth, this is a margin story. Costs are winning. The dividend and clean audit signal a stable foundation, but translating growth into profit is the challenge now.

Primary source: BSE · NSE